NeoTX is leveraging its proprietary Selective T cell Redirection (STR) platform to develop new targeted immunotherapies. STR binds a genetically engineered bacterial determinant to the tumor surface while simultaneously activating immune cells away from the suppressive tumor environment to mount an antibacterial response. The technology effectively converts a weak immune response against the tumor to a powerful, yet safe, native antibacterial immune reaction.